Appendix Table F124. Clinical outcomes after PFMT combined with biofeedback compared to PFMT alone (results from RCTs pooled with random effects models)

Outcome	Reference	Active n/N	Control n/N	Rate active/control	Relative risk (95% CI)	Weight, %	Absolute risk difference (95% CI)	Weight, %
Continence	Berghmans, 1996[487]	5/20	3/20	25/15	1.67 (0.46; 6.06)	7.05	0.1 (-0.146; 0.346)	12.53
Continence	Glavind, 1996[534]	11/20	3/20	55/15	3.67 (1.20; 11.19)	8.95	0.4 (0.132; 0.668)	11.19
Continence	Morkved, 2002[574]	19/53	14/50	36/28	1.28 (0.72; 2.27)	21.85	0.078 (-0.101; 0.258)	17.73
Continence	Burgio, 2002[503]	15/73	11/75	20/15	1.40 (0.69; 2.84)	17.15	0.059 (-0.064; 0.181)	23.68
Continence UD	Goode, 2003[536]	18/66	25/67	28/38	0.73 (0.44; 1.21)	24.8	-0.1 (-0.258; 0.058)	19.82
Continence	Wang, 2004[611]	15/38	12/40	38/30	1.32 (0.71; 2.44)	20.2	0.095 (-0.116; 0.305)	15.05
Pooled		82/270	68/272	30/25	1.27 (0.88; 1.85)	100	0.079 (-0.031; 0.189)	100
Heterogeneity P value, I squared,%					0.147	38.80%	0.065	51.80%
Treatment failure	Morkved, 2002[574]	1/53	3/50	2/6	0.31 (0.03; 2.92)	66.52	-0.041 (-0.116; 0.034)	74.27
Treatment failure	Glavind, 1996[534]	0/20	1/20	0/5	0.33 (0.01; 7.72)	33.48	-0.05 (-0.178; 0.078)	25.73
Pooled		1/73	4/70	1/6	0.32 (0.05; 1.98)	100	-0.043 (-0.108; 0.022)	100
Heterogeneity P value, I squared,%					0.98	0.00%	0.907	0.00%